The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice

Molecules. 2022 Apr 25;27(9):2755. doi: 10.3390/molecules27092755.

Abstract

Here, we explored the possible interaction between duloxetine and SEP-363856 (SEP-856) in depression-related reactions. The results showed that oral administration of duloxetine showed powerful antidepressant-like effects in both the forced swimming test (FST) and the suspension tail test (TST). SEP-856 orally administered alone also exerted an antidepressant-like effect in FST and TST, especially at doses of 0.3, 1, and 10 mg/kg. In addition, duloxetine (15 mg/kg) and SEP-856 (15 mg/kg) both showed antidepressant-like effects in the sucrose preference test (SPT). Most importantly, in the above experiments, compared with duloxetine alone, the simultaneous use of duloxetine and SEP-856 caused a more significant antidepressant-like effect. It is worth noting that doses of drug combination in FST and TST did not change the motor activities of mice in the open-field test (OFT). Thus, duloxetine and SEP-856 seem to play a synergistic role in regulating depression-related behaviors and might be beneficial for refractory depression.

Keywords: SEP-363856; antidepressant-like effect; co-administration; depression; duloxetine.

MeSH terms

  • Animals
  • Antidepressive Agents* / pharmacology
  • Depression / drug therapy
  • Duloxetine Hydrochloride / pharmacology
  • Hindlimb Suspension / methods
  • Mice
  • Pyrans*
  • Swimming

Substances

  • Antidepressive Agents
  • Pyrans
  • SEP-363856
  • Duloxetine Hydrochloride